A pancancer analysis of histone deacetylase 3 in human tumors

Hao Chen,Fan Xu,Anqi Qin,Shuai Guo,Ge Zhang,Bo Yu,Quanhui Zheng

DOI: https://doi.org/10.21037/tcr-23-1228

2024-02-02

Translational Cancer Research

Abstract:Keywords: Histone deacetylase 3 ( HDAC3 ); pancancer; DNA methylation; diagnosis

oncology

What problem does this paper attempt to address?

Histone Deacetylase 3 Promotes Pancreatic Cancer Cell Proliferation, Invasion And Increases Drug-Resistance Through Histone Modification Of P27, P53 And Bax

Feng Jiao,Hai Hu,Cuncun Yuan,Ziliang Jin,Zhen Guo,Liwei Wang,Lei Wang

DOI: https://doi.org/10.3892/ijo.2014.2568

2014-01-01

International Journal of Oncology

Abstract:Pancreatic cancer is one of the most aggressive solid malignancies with a dismal survival rate. Recent studies have shown that high expression levels of histone deacetylase 3 (HDAC3) correlate with malignant phenotype. However, the expression patterns and biological role of HDAC3 in pancreatic cancer remain unclear. In this study, our data showed that a higher level of HDAC3 protein expression was found in pancreatic cancer as compared to paired paracancerous tissues. Consistently, higher expression level of HDAC3 was found in all of the eight pancreatic cancer cell lines relative to human pancreatic ductal epithelial cells (HPDE). In addition, further function analysis revealed that HDAC3 can function as oncogenic protein, which could promote pancreatic cancer cell proliferation, migration and invasion, and may increase drug resistance. Moreover, the functional involvement of HDAC3 was partially correlated with post-induction repression of P53, P27 and Bax gene transcription, acting via H3K9 deacetylation. Taken together, our data suggest that HDAC3 participates in the pathogenesis and progression of pancreatic cancer through histone modification, which might be a pivotal epigenetic target against this devastating disease.
HDAC3 Deficiency Promotes Liver Cancer Through a Defect in H3K9ac/H3K9me3 Transition

Hongjie Ji,Yongjie Zhou,Xiang Zhuang,Yongjie Zhu,Zhenru Wu,Yannrong Lu,Shengfu Li,Yong Zeng,Qing R. Lu,Yanying Huo,Yujun Shi,Hong Bu

DOI: https://doi.org/10.1158/0008-5472.can-18-3767

IF: 11.2

2019-01-01

Cancer Research

Abstract:DNA damage triggers diverse cancers, particularly hepatocellular carcinoma (HCC), but the intrinsic link between DNA damage and tumorigenesis remains unclear. Because of its role as an epigenetic and transcriptional regulator, histone deacetylase 3 (HDAC3) is essential for DNA damage control and is often aberrantly expressed in human HCC. In this study, we used individual class I HDAC member-deficient mice to demonstrate that K9 in histone H3 (H3K9), which is the critical site for the assembly of DNA damage response complexes, is exclusively targeted by HDAC3. Ablation of HDAC3 disrupted the deacetylation and consequent trimethylation of H3K9 (H3K9me3), the first step in double-strand break repair, and led to the accumulation of damaged DNA. Simultaneously, hyperacetylated H3K9 (H3K9ac) served as a transcriptional activator and enhanced multiple signaling pathways to promote tumorigenesis. Together, these results show that HDAC3 targets the H3K9ac/H3K9me3 transition to serve as a critical regulator that controls both DNA damage repair and the transcription of many tumor-related genes. Moreover, these findings provide novel insights into the link between DNA damage and transcriptional reprogramming in tumorigenesis. Significance: These findings show that HDAC3 exclusively regulates H3K9ac in response to DNA damage, and loss of HDAC3 activity shifts the balance from DNA damage control to protumorigenic transcriptional activity.
Clinical Significance of Expression of Histone Deacetylase 3 in Hepatocellular Carcinoma

朱柯亭,武振汝,卢徐锋,纪洪杰,周永杰,曹潇月,朱永杰,步宏,石毓君

DOI: https://doi.org/10.11569/wcjd.v25.i10.922

2017-01-01

Abstract:AIM To detect the expression of histone deacetylase 3 (HDAC3) in hepatocellular carcinoma (HCC) and analyze its clinicopathological significance.METHODS Immunohistochemistry was performed in 60 pairs of HCC tissues and tumor-adjacent normal tissues.The relationship of HDAC3 expression with clinical and pathological features and overall survival was analyzed statistically.RESULTS HDAC3 expression was significantly upregulated in the HCC specimens compared to corresponding normal tissues (P ＜ 0.05).The expression of HDAC3 in HCC had no significant correlation with gender,age,history of hepatitis B virus infection,TNM stage,pathological classification,α-fetoprotein level,liver cirrhosis,tumor size,or tumor number (P ＞ 0.05).There was a positive correlation between HDAC3 and p-STAT3 expression in HCC tissues (r2 =0.622,P ＜ 0.001).However,HDAC3 expression had a significant correlation with tumor recurrence (P ＜ 0.05).The overall survival of postoperative HCC patients in the HDAC3 positive group was obviously poorer than that of patients in the HDAC3 negative group (P ＜ 0.05),suggesting that high HDAC3 expression is associated with a poor prognosis in HCC patients.CONCLUSION The up-regulated expression of HDAC3 may be closely related with the occurrence and development of HCC.
HDAC3 Inhibition Promotes Antitumor Immunity by Enhancing CXCL10-Mediated Chemotaxis and Recruiting of Immune Cells

Lili Li,Shumin Hao,Meiling Gao,Junxiao Liu,Xin Xu,Jianfei Huang,Genhong Cheng,Heng Yang

DOI: https://doi.org/10.1158/2326-6066.CIR-22-0317

2023-05-03

Abstract:It is generally believed that histone deacetylase (HDAC) inhibitors, which represent a new class of anticancer agents, exert their antitumor activity by directly causing cell-cycle arrest and apoptosis of tumor cells. However, in this study, we demonstrated that class I HDAC inhibitors, such as Entinostat and Panobinostat, effectively suppressed tumor growth in immunocompetent but not immunodeficient mice. Further studies with Hdac1, 2, or 3 knockout tumor cells indicated that tumor-specific inactivation of HDAC3 suppressed tumor growth by activating antitumor immunity. Specifically, we found that HDAC3 could directly bind to promotor regions and inhibit the expression of CXCL9, 10, and 11 chemokines. Hdac3-deficient tumor cells expressed high levels of these chemokines, which suppressed tumor growth in immunocompetent mice by recruiting CXCR3+ T cells into the tumor microenvironment (TME). Furthermore, the inverse correlation between HDAC3 and CXCL10 expression in hepatocellular carcinoma tumor tissues also suggested HDAC3 might be involved in antitumor immune regulation and patient survival. Thus, our studies have illustrated that HDAC3 inhibition suppresses tumor growth by enhancing immune cell infiltration into the TME. This antitumor mechanism may be helpful in guiding HDAC3 inhibitor-based treatment.
Expression and Regulation Network of HDAC3 in Acute Myeloid Leukemia and the Implication for Targeted Therapy Based on Multidataset Data Mining

Minhua Li,Feifei Lan,Chen Li,Ning Li,Xiaojie Chen,Yueyuan Zhong,Yue Yang,Yingqi Shao,Yi Kong,Xinming Li,Danny Wu,Jingyu Zhang,Wenqing Chen,Zesong Li,Xiao Zhu

DOI: https://doi.org/10.1155/2022/4703524

IF: 2.809

2022-03-14

Computational and Mathematical Methods in Medicine

Abstract:Background. Histone deacetylase 3 (HDAC3) plays an important role in the development and progression of a variety of cancers, but its regulatory mechanism in acute myeloid leukemia (LAML) is not entirely understood. Methods. We analyzed the expression of HDAC3 in normal and cancerous tissues using Oncomine, UALCAN, and GEO databases. Changes of the HDAC3 gene were analyzed by cBioPortal. The genes coexpressed with HDAC3 were analyzed by WebGestalt, and the predicted signaling pathways in KEGG were discussed. Results. We discovered that the expression of HDAC3 was elevated in some types of acute myeloid leukemia. The HDAC3 gene has a strong positive correlation with SLC25A5, NDUFA2, Cox4I1, and EIF3K, which regulate cell growth and development. HDAC3 transcription is higher in patients with FLT3 mutation than in healthy people. HDAC3 can be directly involved in regulating the thyroid hormone signaling pathway. MEF2D is directly involved in the cGMP-PKG signaling pathway, and the HDAC3 gene has a strong synergistic relationship with MEF2D. HDAC3 is indirectly involved in the cGMP-PKG signaling pathway, thereby indirectly regulating the expression levels of p53 and p21 genes in patients with LAML. Genomics of Drug Sensitivity in Cancer (GDSC) database analysis revealed that the application of the HDAC3 inhibitor can inhibit the proliferation of leukemia cells. Conclusions. Therefore, our data suggest that HDAC3 may be a possible therapeutic target for acute myeloid leukemia.

mathematical & computational biology
Histone deacetylase 3 inhibits expression of PUMA in gastric cancer cells

Lifeng Feng,Min Pan,Jie Sun,Haiqi Lu,Qi Shen,Shengjie Zhang,Tingting Jiang,Liangyi Liu,Wei Jin,Yan Chen,Xian Wang,Hongchuan Jin

DOI: https://doi.org/10.1007/s00109-012-0932-x

2012-01-01

Journal of Molecular Medicine

Abstract:During cancer development, tumor suppressor genes were silenced by promoter methylation or histone deacetylation. Histone deacetylases (HDACs) are important to maintain histone deacetylation. HDAC inhibitors (HDACis) were thus proposed as a new therapeutic approach to cancer. The current study aims to understand the effect and molecular mechanisms of HDACis on gastric cancer cells. Trichostatin A (TSA) significantly inhibited the growth of gastric cancer cells by inducing apoptosis. Gene profiling results showed PUMA (p53 upregulated modulator of apoptosis) as one of 122 genes upregulated in TSA-treated gastric cancer cells. PUMA was downregulated in gastric cancer cell lines and primary gastric carcinoma tissues. Patients with low PUMA expression had significant decreases in overall survival (HR, 2.04; p = 0.047). Ectopic PUMA expression inhibited the growth of gastric cancer cells while PUMA depletion promoted cellular growth. The knockdown of HDAC3 but not other HDACs upregulated PUMA expression. HDAC3 could bind to PUMA promoter, which was abrogated after TSA treatment. In contrast to TSA and SB, HDAC3 siRNA failed to upregulate p53 expression but promoted the interaction of p53 with PUMA promoter. In summary, proapoptotic PUMA was downregulated in gastric cancer and its mRNA expression level is a valuable prognosis factor for gastric cancer. HDAC3 is important to downregulate PUMA expression in gastric cancer and HDACis, like TSA, promoted PUMA expression through stabilizing p53 in addition to HDAC3 inhibition. In combination with chemotherapy, targeting HDAC3 might be a promising strategy to induce apoptosis of gastric cancer cells.
Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications.

Zhiming Li,Wei-Guo Zhu

DOI: https://doi.org/10.7150/ijbs.9067

2014-01-01

International Journal of Biological Sciences

Abstract:Genetic abnormalities have been conventionally considered as hallmarks of cancer. However, studies over the past decades have demonstrated that epigenetic regulation also participates in the development of cancer. The fundamental patterns of epigenetic components, such as DNA methylation and histone modifications, are frequently altered in tumor cells. Acetylation is one of the best characterized modifications of histones, which is controlled by histone acetyltransferases (HATs) and histone deacetylases (HDACs). HDACs are a group of enzymes which catalyze the removal of the acetyl groups of both histones and non-histone proteins. HDACs are involved in modulating most key cellular processes, including transcriptional regulation, apoptosis, DNA damage repair, cell cycle control, autophagy, metabolism, senescence and chaperone function. Because HDACs have been found to function incorrectly in cancer, various HDAC inhibitors are being investigated to act as cancer chemotherapeutics. The primary purpose of this paper is to summarize recent studies of the links between HDACs and cancer, and further discuss the underlying mechanisms of anti-tumor activities of HDAC inhibitors and clinical implications.
HDAC3 Inhibition Upregulates PD-L1 Expression in B-Cell Lymphomas and Augments the Efficacy of Anti-PD-L1 Therapy

Siyu Deng,Qianwen Hu,Heng Zhang,Fang Yang,Cheng Peng,Chuanxin Huang

DOI: https://doi.org/10.1158/1535-7163.mct-18-1068

2019-01-01

Molecular Cancer Therapeutics

Abstract:Programmed cell-death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) pathway blockade is a promising therapy for the treatment of advanced cancers, including B-cell lymphoma. The clinical response to PD-1/PD-L1 immunotherapy correlates with PD-L1 levels on tumor cells and other cells in the tumor microenvironment. Hence, it is important to understand the molecular mechanisms that regulate PD-L1 expression. Here, we report that histone deacetylase 3 (HDAC3) is a crucial repressor of PD-L1 transcription in B-cell lymphoma. Pan-HDACs or selective HDAC3 inhibitors could rapidly increase histone acetylation and recruitment of bromodomain protein BRD4 at the promoter region of PD-L1 gene, leading to activation of its transcription. Mechanically, HDAC3 and its putative associated corepressor SMRT were recruited to the PD-L1 promoter by the transcriptional repressor BCL6. In addition, HDAC3 inhibition reduced DNA methyltransferase 1 protein levels to indirectly activate PD-L1 transcription. Finally, HDAC3 inhibition increased PD-L1 expression on dendritic cells in the tumor microenvironment. Combining selective HDAC3 inhibitor with anti-PD-L1 immunotherapy enhanced tumor regression in syngeneic murine lymphoma model. Our findings identify HDAC3 as an important epigenetic regulator of PD-L1 expression and implicate combination of HDAC3 inhibition with PD-1/PD-L1 blockade in the treatment of B-cell lymphomas.
Histone deacetylase 3 inhibits new tumor suppressor gene DTWD1 in gastric cancer.

Yanning Ma,Yongfang Yue,Min Pan,Jie Sun,Jue Chu,Xiaoying Lin,Wenxia Xu,Lifeng Feng,Yan Chen,Dingwei Chen,Vivian Y Shin,Xian Wang,Hongchuan Jin

2015-01-01

American journal of cancer research

Abstract:Cancer epigenetics plays an important role in the pathogenesis of many cancers including gastric cancer. Histone deacetylases (HDACs) emerge as exciting therapeutic targets for cancer treatment and prevention. In this study, we identified DTWD1 as one of the 122 genes upregulated after treatment of trichostatin A (TSA) in two gastric cancer cell lines. Moreover, DTWD1 was downregulated in gastric cancer cell lines and primary gastric carcinoma tissues. It was further identified as the new target of p53. Then we revealed that HDAC3 downregulated DTWD1 by disrupting the interaction of p53 with DTWD1 promoter. Furthermore, DTWD1 functioned as a tumor suppressor by downregulating cyclin B1 expression to inhibit proliferation. In summary, as the new p53 target gene, DTWD1 was downregulated in gastric cancer by HDAC3 and acted as a novel tumor suppressor gene. Specific inhibitors of HDAC3 might be a new approach for gastric cancer treatment by activating DTWD1 expression.
Expression of histone deacetylase 3 and P21 in colorectal carcinoma and its relationship with the clinicopathological parameters

TANG Jian,CHEN Jin-xian,WAN Bo-shun,WANG Zheng,ZHANG Xi-wen

2009-01-01

Abstract:Objective To investigate the expression of histone deacetylase 3(HDAC3)and P21 in colorectal carcinoma,and its relationship with the clinicopathotogical parameters,and the clinical staging.Methods Western blot was used in the 30 clinical cases to check the difference in expression of HDAC3 and P21 protein in the colorectal carcinoma tissue and in the neighboring normal mucosa,and also its relationship with the clinicopathological parameters was analyzed.Results There was an obvious difference between the expression of HDAC3 and P21 in the colorectal carcinoma proper and in the neighboring normal mucosa,which was statistically meaningful based on semi-quantity analysis(both P=0.000).The expression level of HDAC3 had no relationship with the pathological staging of the colorectal carcinoma.Conclusions The fact that the expression of HDAC3 increased significantly in colorectal carcinoma while that of P21 dropped dramatically indicates:abnormal hyperplasia of colonic mucosa might be caused by HDAC3 inhibiting the expression of P21.Both HDAC3 and P21 play significant roles in the development of colorectal carcinoma.
Aberrant expression of nuclear HDAC3 and cytoplasmic CDH1 predict a poor prognosis for patients with pancreatic cancer.

Feng Jiao,Hai Hu,Ting Han,Meng Zhuo,Cuncun Yuan,Haiyan Yang,Lei Wang,Liwei Wang

DOI: https://doi.org/10.18632/oncotarget.7663

2016-01-01

Oncotarget

Abstract:Previous studies showed that aberrant CDH1 or/and HDAC3 localization is essential for the progression of some human cancers. Here, we investigate the prognostic significance of aberrant CDH1 and HDAC3 localization in 84 pancreatic cancer patients. Our results show that increases in both membrane and cytoplasmic CDH1 correlate with lymph node metastasis (P = 0.026 and P < 0.001, respectively) and clinical stage (P = 0.020 and P < 0.001, respectively). Increased nuclear HDAC3 correlates with lymph node metastasis (P < 0.001) and advanced clinical stage (P < 0.001), but increased cytoplasmic HDAC3 does not (P > 0.05). Multivariate analysis showed that nuclear HDAC3 and cytoplasmic CDH1 (P = 0.001 and P = 0.010, respectively), as well as tumor differentiation (P = 0.009) are independent prognostic factors. Most importantly, patients with high co-expression of nuclear HDAC3 and cytoplasmic CDH1 had shorter survival times (P < 0.001), more frequent lymph node metastasis (P < 0.001), and advanced clinical stage (P < 0.001). Our studies provide convincing evidence that nuclear HDAC3 and cytoplasmic CDH1 have independent prognostic value in pancreatic cancer and provide novel targets for prognostic therapeutics.
Identification of Histone Deacetylase 3 As a Biomarker for Tumor Recurrence Following Liver Transplantation in HBV-associated Hepatocellular Carcinoma.

Li-Ming Wu,Zhe Yang,Lin Zhou,Feng Zhang,Hai-Yang Xie,Xiao-Wen Feng,Jian Wu,Shu-Sen Zheng

DOI: https://doi.org/10.1371/journal.pone.0014460

IF: 3.7

2010-01-01

PLoS ONE

Abstract:BACKGROUND:Recent studies have shown that high expression levels of class I histone deacetylases (HDACs) correlate with malignant phenotype and poor prognosis in some human tumors. However, the expression patterns and prognostic role of class I HDAC isoforms in hepatocellular carcinoma (HCC) remain unclear. METHODOLOGY/PRINCIPAL FINDINGS:The expression patterns and clinical significance of class I HDAC isoforms were assessed by immunohistochemistry in a cohort of 43 hepatitis B virus-associated HCC patients treated with liver transplantation. In addition, the effects of HDAC inhibition on HCC cell behavior were investigated by knockdown of the HDAC isoform with short interfering RNA. Class I HDACs were highly expressed in a subset of HCCs with positivity for HDAC1 in 51.2%, HDAC2 in 48.8%, and HDAC3 in 32.6% of cases. The expression levels of HDAC isoforms were significantly associated with the proliferation index of HCC. Kaplan-Meier curves showed that a high expression level of HDAC2 or HDAC3 implicated significantly reduced recurrence-free survival. Cox proportional hazards model analysis revealed HDAC3 overexpression was an unfavorable independent prognostic factor (P = 0.002; HR 3.907). In vitro, inhibition of HDAC2 and HDAC3, but not HDAC1, suppressed proliferation and the invasiveness of liver cancer cells. CONCLUSIONS/SIGNIFICANCE:Our findings demonstrate that HDAC3 plays a significant role in regulating tumor cell proliferation and invasion, and it could be served as a candidate biomarker for predicting the recurrence of hepatitis B virus-associated HCC following liver transplantation and a potential therapeutic target.
H3K36 trimethylation-mediated biological functions in cancer

Chu Xiao,Tao Fan,He Tian,Yujia Zheng,Zheng Zhou,Shuofeng Li,Chunxiang Li,Jie He

DOI: https://doi.org/10.1186/s13148-021-01187-2

2021-10-29

Clinical Epigenetics

Abstract:Abstract Histone modification is an important form of epigenetic regulation. Thereinto, histone methylation is a critical determination of chromatin states, participating in multiple cellular processes. As a conserved histone methylation mark, histone 3 lysine 36 trimethylation (H3K36me3) can mediate multiple transcriptional-related events, such as the regulation of transcriptional activity, transcription elongation, pre-mRNA alternative splicing, and RNA m 6 A methylation. Additionally, H3K36me3 also contributes to DNA damage repair. Given the crucial function of H3K36me3 in genome regulation, the roles of H3K36me3 and its sole methyltransferase SETD2 in pathogenesis, especially malignancies, have been emphasized in many studies, and it is conceivable that disruption of histone methylation regulatory network composed of “writer”, “eraser”, “reader”, and the mutation of H3K36me3 codes have the capacity of powerfully modulating cancer initiation and development. Here we review H3K36me3-mediated biological processes and summarize the latest findings regarding its role in cancers. We highlight the significance of epigenetic combination therapies in cancers.

oncology,genetics & heredity
HDAC3 Expression Correlates with the Prognosis and Grade of Patients with Glioma: A Diversification Analysis Based on Transcriptome and Clinical Evidence.

Sheng Zhong,Yuxiang Fan,Bo Wu,Yannan Wang,Shanshan Jiang,Junliang Ge,Cong Hua,Gang Zhao,Yong Chen,Haiyang Xu

DOI: https://doi.org/10.1016/j.wneu.2018.07.076

IF: 2.21

2018-01-01

World Neurosurgery

Abstract:OBJECTIVE:This study aimed to clarify the relationship between histone deacetylase 3 (HDAC3) expression and the prognosis as well as the grade of patients with glioma. METHODS:The quantitative real-time polymerase chain reaction was profiled to examine the HDAC3 expression in glioma and normal glial cell lines. An Oncomine database analysis and prognosis analysis were performed. The correlation between World Health Organization (WHO) grade and HDAC3 was analyzed by Spearman rank correlation test. A meta-analysis was performed to confirm the conclusion. RESULTS:HDAC3 RNA overexpression in glioma cell lines was detected (P < 0.05). Four data sets were screened from the Oncomine database and showed that the expression level of HDAC3 was consistently higher in glioma than in normal tissue (P < 0.001). The prognostic analysis of 325 glioma samples from the Chinese Glioma Genome Atlas showed that patients with low HDAC3 expression had significantly better overall survival (OS) and progression-free survival (PFS) than did patients with high HDAC3 expression [hazard ratio [HR], 1.992; 95% confidence interval [CI], 1.490-2.662; P < 0.0001 and HR, 1.874; 95% CI, 1.412-2.487; P < 0.0001, respectively]. Both the WHO grade III group and the WHO grade IV group expressed significantly higher messenger RNA (mRNA) level than did the WHO grade II group (P < 0.05). Four cohort studies consisting of 490 patients were included in the meta-analysis. The pooled data of subgroup analysis showed significantly longer OS in low HDAC3 mRNA level [HR, 3.38; 95% CI, 1.80-6.37; P = 0.0002]. CONCLUSIONS:HDAC3 mRNA was expressed more in glioma than in the normal glial cell line. Low HDAC3 mRNA expression levels predicted better OS. HDAC3 expression could be a biomarker to discriminate glioma grade.
Additional File 13 of Pan-cancer Analysis Revealed H3K4me1 at Bivalent Promoters Premarks DNA Hypermethylation During Tumor Development and Identified the Regulatory Role of DNA Methylation in Relation to Histone Modifications

Lu Yang,Qiang Cao,Yue Yu,Yazhou Sun,Xuan Jiang,Xin Li

DOI: https://doi.org/10.6084/m9.figshare.22757346

2023-01-01

Abstract:Additional file 13: Supplementary Table S1. Summary of 5 gene groups in different cancer types.
Systematic Analysis of Histone Acetylation Regulators Across Human Cancers.

Congkuan Song,Xinfei Liu,Weichen Lin,Kai Lai,Shize Pan,Zilong Lu,Donghang Li,Ning Li,Qing Geng

DOI: https://doi.org/10.1186/s12885-023-11220-7

IF: 4.638

2023-01-01

BMC Cancer

Abstract:BACKGROUND:Histone acetylation (HA) is an important and common epigenetic pathway, which could be hijacked by tumor cells during carcinogenesis and cancer progression. However, the important role of HA across human cancers remains elusive.METHODS:In this study, we performed a comprehensive analysis at multiple levels, aiming to systematically describe the molecular characteristics and clinical relevance of HA regulators in more than 10000 tumor samples representing 33 cancer types.RESULTS:We found a highly heterogeneous genetic alteration landscape of HA regulators across different human cancer types. CNV alteration may be one of the major mechanisms leading to the expression perturbations in HA regulators. Furthermore, expression perturbations of HA regulators correlated with the activity of multiple hallmark oncogenic pathways. HA regulators were found to be potentially useful for the prognostic stratification of kidney renal clear cell carcinoma (KIRC). Additionally, we identified HDAC3 as a potential oncogene in lung adenocarcinoma (LUAD).CONCLUSION:Overall, our results highlights the importance of HA regulators in cancer development, which may contribute to the development of clinical strategies for cancer treatment.
HDAC1: a promising target for cancer treatment: insights from a thorough analysis of tumor functions

Jiaojiao Xie,Rui Liu,Ying Cai,Dina Liu

DOI: https://doi.org/10.21037/tcr-24-23

2024-11-02

Translational Cancer Research

Abstract:Keywords: Histone deacetylase 1 (HDAC1); epigenetic enzyme; tumorigenesis; inflammation; cancer therapy

oncology
High Histone Deacetylase 2/3 Expression in Non-Functioning Pituitary Tumors

Wenxiu Zhao,Xiaobin Jiang,Karrin Weisenthal,Jun Ma,Erin M Botticelli,Yunli Zhou,E Tessa Hedley-Whyte,Baiyao Wang,Brooke Swearingen,Roy J Soberman,Anne Klibanski,Xun Zhang

DOI: https://doi.org/10.3389/fonc.2022.875122

2022-05-13

Abstract:Epigenetic modification of chromatin is involved in non-malignant pituitary neoplasia by causing abnormal expression of tumor suppressors and oncogenes. These changes are potentially reversible, suggesting the possibility of targeting tumor cells by restoring the expression of epigenetically silenced tumor suppressors. The role of the histone deacetylase (HDAC) family in pituitary tumorigenesis is not known. We report that HDAC2 and 3, Class I HDAC members, are highly expressed in clinically non-functioning pituitary adenomas (NFPAs) compared to normal pituitary (NP) samples as determined by RT-PCR and immunohistochemical staining (IHC). Treatment of a human NFPA derived folliculostellate cell line, PDFS, with the HDAC3 inhibitor RGFP966 for 96 hours resulted in inhibition of cell proliferation by 70%. Furthermore, the combination of RGFP966 with a methyltransferase/DNMT inhibitor, 5'-aza-2'-deoxycytidine, led to the restoration of the expression of several tumor suppressor genes, including STAT1, P16, PTEN, and the large non-coding RNA tumor suppressor MEG3, in PDFS cells. Our data support the hypothesis that both histone modification and DNA methylation are involved in the pathogenesis of human NFPAs and suggest that targeting HDACs and DNA methylation can be incorporated into future therapies.
Exploring the role of histone deacetylase inhibitors in cancer development and therapeutic potential

C Zhang,H X Li,Y Man,Z H Jiang,P Yin,K Yu

DOI: https://doi.org/10.26402/jpp.2024.2.01

Abstract:The process of acetylation and deacetylation of histones within the nucleus operates within a dynamic equilibrium. Histone acetyltransferases (HATs) and histone deacetylases (HDACs) collaboratively and precisely regulate normal gene transcription and expression. Any disorder in the activity of HATs/HDACs can lead to uncontrolled gene expression, consequently resulting in tumorigenesis. Histone deacetylase inhibitors (HDACIs) have the capacity to block the cell cycle, thereby restraining tumor cell proliferation and tumor growth. Also, HDACIs exhibit a significant capability to diminish the expression of apoptosis protein inhibitors such as Bcl-2 and B-cell lymphoma-extra-large (Bcl-xL), while concurrently up-regulating pro-apoptotic proteins such as Bax, Bad, and Bim. Also, HDACIs demonstrate the ability to inhibit tumor cell angiogenesis. Representing a new category of targeted anti-cancer therapeutics, HDACIs possess the capability to restore the expression of tumor suppressor genes, induce apoptosis, and stimulate cell differentiation. Additionally, they exert anti-cancer effects through diverse pathways both in vivo and in vitro, thereby presenting promising prospects in tumor therapy. This review delves into the involvement of HDACs in cancer pathology and the therapeutic potential of HDACIs as emerging drugs in cancer treatment.
DNA Methylation and Histone Deacetylation: Interplay and Combined Therapy in Cancer

Yi Qiu,Daniel Shabashvili,Xuehui Li,Priya Kumari,Min Chen,Maria Zajac‐Kaye

DOI: https://doi.org/10.5772/35977

2012-01-01

Abstract:In mammalian cells, DNA can be modified by methylation of cytosine residues in CpG dinucleotides, and the N-terminal tails of histone proteins are subject to a wide range of different modifications, including acetylation, methylation, phosphorylation and ubiquitylation. All of these chemical changes have a substantial influence on chromatin structure and gene expression. These epigenetic modification patterns can be regarded as heritable marks over many cell generations. Importantly, patterns and levels of DNA methylation and histone acetylation/deacetylation are profoundly altered in human cancers. Inhibitors of DNA methytransferases (DNMTs) and histone deacetylases (HDACs) have been shown to inhibit tumor growth by reactivating epigenetically silenced tumor suppressor genes. Although DNA methylation and histone deacetylation are carried out by different chemical reactions and require different sets of enzymes, it seems that there is a biological relationship between the two systems in modulating gene repression programming. Accumulating evidence also suggests that this epigenetic cross-talk may be involved in gene transcription and aberrant gene silencing in tumors. Thus, combined therapy with both DNMT and HDAC inhibitors can be a promising approach for cancer treatment.

A pancancer analysis of histone deacetylase 3 in human tumors

Histone Deacetylase 3 Promotes Pancreatic Cancer Cell Proliferation, Invasion And Increases Drug-Resistance Through Histone Modification Of P27, P53 And Bax

HDAC3 Deficiency Promotes Liver Cancer Through a Defect in H3K9ac/H3K9me3 Transition

Clinical Significance of Expression of Histone Deacetylase 3 in Hepatocellular Carcinoma

HDAC3 Inhibition Promotes Antitumor Immunity by Enhancing CXCL10-Mediated Chemotaxis and Recruiting of Immune Cells

Expression and Regulation Network of HDAC3 in Acute Myeloid Leukemia and the Implication for Targeted Therapy Based on Multidataset Data Mining

Histone deacetylase 3 inhibits expression of PUMA in gastric cancer cells

Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications.

HDAC3 Inhibition Upregulates PD-L1 Expression in B-Cell Lymphomas and Augments the Efficacy of Anti-PD-L1 Therapy

Histone deacetylase 3 inhibits new tumor suppressor gene DTWD1 in gastric cancer.

Expression of histone deacetylase 3 and P21 in colorectal carcinoma and its relationship with the clinicopathological parameters

Aberrant expression of nuclear HDAC3 and cytoplasmic CDH1 predict a poor prognosis for patients with pancreatic cancer.

Identification of Histone Deacetylase 3 As a Biomarker for Tumor Recurrence Following Liver Transplantation in HBV-associated Hepatocellular Carcinoma.

H3K36 trimethylation-mediated biological functions in cancer

HDAC3 Expression Correlates with the Prognosis and Grade of Patients with Glioma: A Diversification Analysis Based on Transcriptome and Clinical Evidence.

Additional File 13 of Pan-cancer Analysis Revealed H3K4me1 at Bivalent Promoters Premarks DNA Hypermethylation During Tumor Development and Identified the Regulatory Role of DNA Methylation in Relation to Histone Modifications

Systematic Analysis of Histone Acetylation Regulators Across Human Cancers.

HDAC1: a promising target for cancer treatment: insights from a thorough analysis of tumor functions

High Histone Deacetylase 2/3 Expression in Non-Functioning Pituitary Tumors

Exploring the role of histone deacetylase inhibitors in cancer development and therapeutic potential

DNA Methylation and Histone Deacetylation: Interplay and Combined Therapy in Cancer